vs
弗雷斯特研究公司（FORR）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
弗雷斯特研究公司的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.3倍（$101.1M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -6.5%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $-4.3M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 0.5%）
福雷斯特研究公司是一家全球领先的研究咨询机构，主营业务涵盖行业研究、管理咨询与行业峰会举办，客户群体包括全球大型企业、科技公司与消费领域领军企业，公司总部位于美国马萨诸塞州剑桥市。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
FORR vs PBYI — 直观对比
营收规模更大
FORR
是对方的1.3倍
$75.5M
营收增速更快
PBYI
高出34.2%
-6.5%
自由现金流更多
PBYI
多$18.7M
$-4.3M
两年增速更快
PBYI
近两年复合增速
0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $101.1M | $75.5M |
| 净利润 | $-33.9M | — |
| 毛利率 | 56.7% | 69.3% |
| 营业利润率 | -36.6% | 22.7% |
| 净利率 | -33.5% | — |
| 营收同比 | -6.5% | 27.7% |
| 净利润同比 | -7941.4% | — |
| 每股收益（稀释后） | $-1.75 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FORRPBYI
| Q4 25 | $101.1M | $75.5M | ||
| Q3 25 | $94.3M | $54.5M | ||
| Q2 25 | $111.7M | $52.4M | ||
| Q1 25 | $89.9M | $46.0M | ||
| Q4 24 | $108.0M | $59.1M | ||
| Q3 24 | $102.5M | $80.5M | ||
| Q2 24 | $121.8M | $47.1M | ||
| Q1 24 | $100.1M | $43.8M |
净利润FORRPBYI
| Q4 25 | $-33.9M | — | ||
| Q3 25 | $-2.1M | $8.8M | ||
| Q2 25 | $3.9M | $5.9M | ||
| Q1 25 | $-87.3M | $3.0M | ||
| Q4 24 | $432.0K | — | ||
| Q3 24 | $-5.8M | $20.3M | ||
| Q2 24 | $6.3M | $-4.5M | ||
| Q1 24 | $-6.7M | $-4.8M |
毛利率FORRPBYI
| Q4 25 | 56.7% | 69.3% | ||
| Q3 25 | 60.0% | 77.7% | ||
| Q2 25 | 55.5% | 76.5% | ||
| Q1 25 | 55.9% | 77.1% | ||
| Q4 24 | 58.8% | 76.4% | ||
| Q3 24 | 60.5% | 63.9% | ||
| Q2 24 | 57.3% | 77.4% | ||
| Q1 24 | 54.9% | 75.5% |
营业利润率FORRPBYI
| Q4 25 | -36.6% | 22.7% | ||
| Q3 25 | 4.7% | 17.6% | ||
| Q2 25 | 6.2% | 12.7% | ||
| Q1 25 | -97.5% | 8.7% | ||
| Q4 24 | -0.5% | 22.6% | ||
| Q3 24 | -0.7% | 27.4% | ||
| Q2 24 | 9.3% | -4.6% | ||
| Q1 24 | -9.3% | -5.3% |
净利率FORRPBYI
| Q4 25 | -33.5% | — | ||
| Q3 25 | -2.3% | 16.2% | ||
| Q2 25 | 3.5% | 11.2% | ||
| Q1 25 | -97.1% | 6.5% | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | -5.7% | 25.2% | ||
| Q2 24 | 5.2% | -9.6% | ||
| Q1 24 | -6.7% | -11.0% |
每股收益（稀释后）FORRPBYI
| Q4 25 | $-1.75 | $0.26 | ||
| Q3 25 | $-0.11 | $0.17 | ||
| Q2 25 | $0.20 | $0.12 | ||
| Q1 25 | $-4.62 | $0.06 | ||
| Q4 24 | $0.02 | $0.40 | ||
| Q3 24 | $-0.30 | $0.41 | ||
| Q2 24 | $0.33 | $-0.09 | ||
| Q1 24 | $-0.35 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.3M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $126.5M | $130.3M |
| 总资产 | $404.0M | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资FORRPBYI
| Q4 25 | $63.3M | $97.5M | ||
| Q3 25 | $65.1M | $94.4M | ||
| Q2 25 | $67.8M | $96.0M | ||
| Q1 25 | $75.6M | $93.2M | ||
| Q4 24 | $56.1M | $101.0M | ||
| Q3 24 | $62.8M | $96.7M | ||
| Q2 24 | $58.9M | $96.8M | ||
| Q1 24 | $61.4M | $107.2M |
总债务FORRPBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益FORRPBYI
| Q4 25 | $126.5M | $130.3M | ||
| Q3 25 | $157.7M | $115.3M | ||
| Q2 25 | $159.5M | $104.7M | ||
| Q1 25 | $147.4M | $97.1M | ||
| Q4 24 | $229.5M | $92.1M | ||
| Q3 24 | $234.3M | $71.1M | ||
| Q2 24 | $237.1M | $48.5M | ||
| Q1 24 | $230.9M | $51.0M |
总资产FORRPBYI
| Q4 25 | $404.0M | $216.3M | ||
| Q3 25 | $414.2M | $202.9M | ||
| Q2 25 | $436.0M | $194.9M | ||
| Q1 25 | $439.8M | $196.2M | ||
| Q4 24 | $503.9M | $213.3M | ||
| Q3 24 | $505.3M | $220.7M | ||
| Q2 24 | $524.2M | $205.0M | ||
| Q1 24 | $555.7M | $214.1M |
负债/权益比FORRPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.2M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $-4.3M | $14.4M |
| 自由现金流率自由现金流/营收 | -4.2% | 19.1% |
| 资本支出强度资本支出/营收 | 1.1% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $18.1M | $41.7M |
8季度趋势，按日历期对齐
经营现金流FORRPBYI
| Q4 25 | $-3.2M | $14.4M | ||
| Q3 25 | $1.2M | $9.7M | ||
| Q2 25 | $-3.6M | $14.1M | ||
| Q1 25 | $26.7M | $3.6M | ||
| Q4 24 | $-1.8M | $15.6M | ||
| Q3 24 | $264.0K | $11.0M | ||
| Q2 24 | $-2.9M | $1.0M | ||
| Q1 24 | $611.0K | $11.2M |
自由现金流FORRPBYI
| Q4 25 | $-4.3M | $14.4M | ||
| Q3 25 | $524.0K | $9.7M | ||
| Q2 25 | $-4.2M | $14.1M | ||
| Q1 25 | $26.1M | $3.6M | ||
| Q4 24 | $-2.5M | $15.6M | ||
| Q3 24 | $-223.0K | $11.0M | ||
| Q2 24 | $-3.7M | $1.0M | ||
| Q1 24 | $-815.0K | — |
自由现金流率FORRPBYI
| Q4 25 | -4.2% | 19.1% | ||
| Q3 25 | 0.6% | 17.7% | ||
| Q2 25 | -3.8% | 26.8% | ||
| Q1 25 | 29.0% | 7.7% | ||
| Q4 24 | -2.3% | 26.4% | ||
| Q3 24 | -0.2% | 13.7% | ||
| Q2 24 | -3.1% | 2.1% | ||
| Q1 24 | -0.8% | — |
资本支出强度FORRPBYI
| Q4 25 | 1.1% | 0.0% | ||
| Q3 25 | 0.7% | 0.0% | ||
| Q2 25 | 0.5% | 0.0% | ||
| Q1 25 | 0.7% | 0.1% | ||
| Q4 24 | 0.6% | 0.0% | ||
| Q3 24 | 0.5% | 0.0% | ||
| Q2 24 | 0.7% | 0.0% | ||
| Q1 24 | 1.4% | 0.0% |
现金转化率FORRPBYI
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | -0.93× | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | -4.24× | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | -0.46× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
PBYI
暂无分部数据
